Distinguished in Localized Scleroderma

Dr. Vimal H. Prajapati

Dermatology
300 Longwood Ave, Dermatology Program, 
Boston, MA 
Distinguished in Localized Scleroderma
300 Longwood Ave, Dermatology Program, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Vimal Prajapati is a Dermatologist in Boston, Massachusetts. Dr. Prajapati is rated as a Distinguished provider by MediFind in the treatment of Localized Scleroderma. His top areas of expertise are Plaque Psoriasis, Atopic Dermatitis, Generalized Pustular Psoriasis (GPP), and Psoriasis.

His clinical research consists of co-authoring 109 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Localized Scleroderma.

Specialties
Dermatology
Licenses
Pediatric Dermatology in MA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

300 Longwood Ave, Dermatology Program, Boston, MA 02115

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

109 Total Publications

Current Understanding of Seborrheic Dermatitis: Presentation, Diagnosis, and Special Populations.
Current Understanding of Seborrheic Dermatitis: Presentation, Diagnosis, and Special Populations.
Journal: Journal of cutaneous medicine and surgery
Published: September 18, 2025
Similar Doctors
Distinguished in Localized Scleroderma
Dr. Avery H. Lachance
Dermatology
Distinguished in Localized Scleroderma
Dr. Avery H. Lachance
Dermatology

Brigham And Womens Physicians Organization Inc

221 Longwood Ave, 
Boston, MA 
 (0.2 miles away)
617-732-5500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Avery Lachance is a Dermatologist in Boston, Massachusetts. Dr. Lachance is rated as a Distinguished provider by MediFind in the treatment of Localized Scleroderma. Her top areas of expertise are Localized Scleroderma, Eosinophilic Fasciitis, Discoid Lupus Erythematosus (DLE), and Cutaneous Lupus Erythematosus (CLE). Dr. Lachance is currently accepting new patients.

Ruth Ann Vleugels
Distinguished in Localized Scleroderma
Dr. Ruth Ann Vleugels
Dermatology
Distinguished in Localized Scleroderma
Dr. Ruth Ann Vleugels
Dermatology

Brigham Dermatology Associates At Brigham And Womens Hospital

221 Longwood Avenue, 
Boston, MA 
 (0.2 miles away)
617-732-4918
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ruth Vleugels is a Dermatologist in Boston, Massachusetts. Dr. Vleugels and is rated as an Elite provider by MediFind in the treatment of Localized Scleroderma. Her top areas of expertise are Dermatomyositis, Eosinophilic Fasciitis, Cutaneous Lupus Erythematosus (CLE), and Discoid Lupus Erythematosus (DLE).

Distinguished in Localized Scleroderma
Dr. Christina S. Lam
Dermatology
Distinguished in Localized Scleroderma
Dr. Christina S. Lam
Dermatology

Boston University Dermatology Inc

725 Albany St, 
Boston, MA 
 (1.7 miles away)
617-638-7420
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Christina Lam is a Dermatologist in Boston, Massachusetts. Dr. Lam is rated as a Distinguished provider by MediFind in the treatment of Localized Scleroderma. Her top areas of expertise are Cutaneous Lupus Erythematosus (CLE), Discoid Lupus Erythematosus (DLE), Localized Scleroderma, and Systemic Sclerosis (SSc). Dr. Lam is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Prajapati's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile